Purdue and Amneal OxyContin clash ends
Purdue continues OxyContin patent battle
Natee Meepian / iStockphoto.com
Purdue Pharma has settled another patent dispute involving pain drug OxyContin (oxycodone), just weeks after a suit against generics company Amneal Pharmaceuticals came to an end.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Purdue Pharma, Assertio Therapeutics, OxyContin, ANDA, FDA, patent, patent infringement, oxycodone, dismissal, Depomed